Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 7/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PARG | Q86W56 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30319352 | 0.98 | LMNA (0.34) | LMNASMN1; SMN2HTTALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL30319329 | 0.98 | LMNA (0.34) | LMNASMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL30319367 | 0.83 | KAT2B (0.35) | LMNASMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL30319366 | 0.79 | MAPT (0.35) | LMNASMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL30319308 | 0.79 | KAT2B (0.31) | LMNASMN1; SMN2KAT2BDHODH | |
| SCHEMBL26740769 | 0.75 | DHODH (0.35) | LMNASMN1; SMN2KAT2BDHODH | |
| SCHEMBL30595733 | 0.72 | LMNA (0.36) | LMNASMN1; SMN2HTTALDH1A1POLB | |
| SCHEMBL22095392 | 0.71 | BRD4 (0.35) | SMN1; SMN2DHODH | |
| SCHEMBL24097324 | 0.71 | POLB (0.37) | SMN1; SMN2HTTPOLBTSHRENPP1 | |
| SCHEMBL30319342 | 0.71 | POLB (0.37) | SMN1; SMN2HTTPOLBTSHRENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-4161905-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | LMNA 1896/4885SMN1; SMN2 3828/4885HTT 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.